- Home
- PBA vs WAT Comparison
PBA vs WAT Comparison
Compare PBA & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- WAT
- Stock Information
- Founded
- PBA 1997
- WAT 1958
- Country
- PBA Canada
- WAT United States
- Employees
- PBA N/A
- WAT N/A
- Industry
- PBA Oil & Gas Production
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PBA Energy
- WAT Industrials
- Exchange
- PBA Nasdaq
- WAT Nasdaq
- Market Cap
- PBA 21.0B
- WAT 20.1B
- IPO Year
- PBA N/A
- WAT 1995
- Fundamental
- Price
- PBA $37.07
- WAT $344.39
- Analyst Decision
- PBA Buy
- WAT Buy
- Analyst Count
- PBA 1
- WAT 15
- Target Price
- PBA $59.00
- WAT $387.60
- AVG Volume (30 Days)
- PBA 805.7K
- WAT 489.8K
- Earning Date
- PBA 05-08-2025
- WAT 05-06-2025
- Dividend Yield
- PBA 5.29%
- WAT N/A
- EPS Growth
- PBA N/A
- WAT 8.23
- EPS
- PBA 2.13
- WAT 11.02
- Revenue
- PBA $5,653,459,489.00
- WAT $2,983,253,000.00
- Revenue This Year
- PBA $13.50
- WAT $5.16
- Revenue Next Year
- PBA $0.62
- WAT $6.59
- P/E Ratio
- PBA $17.55
- WAT $31.38
- Revenue Growth
- PBA 29.95
- WAT 2.57
- 52 Week Low
- PBA $34.13
- WAT $279.24
- 52 Week High
- PBA $43.44
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- PBA 40.57
- WAT 54.04
- Support Level
- PBA $38.36
- WAT $328.79
- Resistance Level
- PBA $39.74
- WAT $358.29
- Average True Range (ATR)
- PBA 0.73
- WAT 11.77
- MACD
- PBA 0.01
- WAT 3.12
- Stochastic Oscillator
- PBA 5.65
- WAT 83.65
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.